ZA200504239B - Pharmaceutical suspension composition - Google Patents

Pharmaceutical suspension composition

Info

Publication number
ZA200504239B
ZA200504239B ZA200504239A ZA200504239A ZA200504239B ZA 200504239 B ZA200504239 B ZA 200504239B ZA 200504239 A ZA200504239 A ZA 200504239A ZA 200504239 A ZA200504239 A ZA 200504239A ZA 200504239 B ZA200504239 B ZA 200504239B
Authority
ZA
South Africa
Prior art keywords
suspension composition
pharmaceutical suspension
pharmaceutical
composition
suspension
Prior art date
Application number
ZA200504239A
Other languages
English (en)
Inventor
Dickerson Jay
Trimmer Annabelle
Alley Amanda Roop
Mark William
Jaeger David
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200504239B publication Critical patent/ZA200504239B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200504239A 2004-05-25 2005-05-24 Pharmaceutical suspension composition ZA200504239B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/852,946 US20050266031A1 (en) 2004-05-25 2004-05-25 Pharmaceutical suspension composition

Publications (1)

Publication Number Publication Date
ZA200504239B true ZA200504239B (en) 2007-02-28

Family

ID=35425554

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200504239A ZA200504239B (en) 2004-05-25 2005-05-24 Pharmaceutical suspension composition

Country Status (9)

Country Link
US (4) US20050266031A1 (tr)
EP (2) EP2465497A1 (tr)
CN (1) CN1988893A (tr)
CA (1) CA2567075C (tr)
MX (1) MXPA06013481A (tr)
TR (1) TR200501948A2 (tr)
TW (1) TW200600118A (tr)
WO (1) WO2005115353A1 (tr)
ZA (1) ZA200504239B (tr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
US8940796B2 (en) 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
DK2018160T3 (da) 2006-03-16 2012-02-06 Tris Pharma Inc Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
EP1854782B1 (en) * 2006-05-05 2009-09-30 Givaudan Nederland Services B.V. Taste improving composition
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20100104624A1 (en) * 2008-06-11 2010-04-29 Peter Langecker Combination therapy using phosphodiesterase inhibitors
BR112012014962A2 (pt) 2009-12-18 2016-04-05 Exodos Life Sciences Ltd Partnership métodos e composições para formulações líquidas e estáveis de fármacos
US8470375B1 (en) 2010-01-05 2013-06-25 Neos Therapeutics, Lp Method of formulating and designing liquid drug suspensions containing ion exchange resin particles
KR20140012029A (ko) 2010-10-21 2014-01-29 알티유 파머수티컬즈, 엘엘시 즉시 사용가능한 케토로락 제제
WO2013003622A1 (en) 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
BR102012030828A2 (pt) 2012-12-03 2014-09-16 Ems Sa Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
CN103251590B (zh) * 2013-05-13 2014-12-17 中国科学院武汉病毒研究所 一种琥珀酸多西拉敏在制备治疗或预防流感病毒药物中的应用
CN103860462A (zh) * 2014-01-14 2014-06-18 万特制药(海南)有限公司 一种盐酸左西替利嗪糖浆剂及制备方法
EP3154338B1 (en) * 2014-06-10 2020-01-29 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
CN105287554B (zh) * 2014-12-10 2018-10-30 沈阳药科大学 复方抗感冒药组合物及其用途
CN104644993A (zh) * 2015-03-18 2015-05-27 天津中医药大学 一种中药干混悬剂及其制备方法
AU2016270504A1 (en) * 2015-05-29 2017-12-14 Codadose Incorporated Liquid formulations of celecoxib for oral administration
CN106324162B (zh) * 2015-06-17 2018-04-27 深圳海王医药科技研究院有限公司 一种基于中心切割技术鉴定复方感冒药中降解产物的高效液相色谱-飞行时间质谱联用方法
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
JP6827048B2 (ja) 2015-12-08 2021-02-10 バイオマトリカ，インク． 赤血球沈降速度の低下
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US20210290532A1 (en) 2017-11-02 2021-09-23 Max Spielberg Pharmaceutical syrup formulation or suspension
CN109010837B (zh) * 2018-10-25 2021-09-28 千辉药业（安徽）有限责任公司 一种具有高溶解性的塞来昔布组合物
KR20200053746A (ko) 2018-11-09 2020-05-19 (주)아모레퍼시픽 졸-겔 조성물
JP2023508085A (ja) * 2019-12-23 2023-02-28 ヌトラ、エッセンシャル、オテセ、ソシエダッド、リミターダ イブプロフェンおよびフェニレフリンを含んでなる液体組成物
WO2022074630A1 (en) * 2020-10-09 2022-04-14 Auxilla Pharmaceuticals And Research Llp Liquid oral suspension of favipiravir
EP4226923A4 (en) * 2020-12-04 2024-08-21 Laboratorios Silanes S A De C V PHARMACEUTICAL COMPOSITION CONTAINING AN ANALGESIC AND AN ANTIHISTAMINE FOR THE TREATMENT OF RESPIRATORY DISEASES
CN112516083B (zh) * 2020-12-15 2023-02-28 太阳升(亳州)生物医药科技有限公司 布洛芬混悬液及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4145440A (en) * 1977-08-18 1979-03-20 The Upjohn Company Liquid suspension of an aluminum salt of ibuprofen
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US4871733A (en) * 1984-04-09 1989-10-03 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4788220A (en) 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
US4975465A (en) * 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
ES2194863T3 (es) * 1992-11-30 2003-12-01 Kv Pharm Co Materiales farmaceuticos con enmascarado de sabor.
EP0620001A1 (en) 1993-04-16 1994-10-19 McNEIL-PPC, INC. Aqueous pharmaceutical suspension and process for preparation thereof
RU2150942C1 (ru) 1993-10-01 2000-06-20 Синтекс (Ю.ЭС.ЭЙ.) Инк. Оральные суспензии, содержащие высокие дозы мофетила микофенолята
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
IT1286496B1 (it) 1996-11-20 1998-07-15 Leetrim Ltd Dublin Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
WO1998058640A1 (en) * 1997-06-23 1998-12-30 Mcneil-Ppc Ibuprofen and diphenhydramine analgesics
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
US6475539B1 (en) * 1998-05-07 2002-11-05 Abbott Laboratories Nutritionally complete low pH enteral formula
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6190701B1 (en) * 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US6515008B1 (en) * 2000-05-04 2003-02-04 Smithkline Beecham Corporation Formulation
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
BR0207930A (pt) * 2001-03-05 2004-03-02 Ortho Mcneil Pharm Inc Composições farmacêuticas lìquidas com sabor mascarado
JP4365107B2 (ja) * 2001-05-25 2009-11-18 エスエス製薬株式会社 医薬組成物
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
US6890558B2 (en) * 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CA2486553C (en) * 2002-06-17 2012-01-10 Taro Pharmaceuticals U.S.A., Inc. Ibuprofen suspension
US20080139528A1 (en) * 2003-12-10 2008-06-12 Pujara Chetan P Cefdinir oral suspension

Also Published As

Publication number Publication date
EP1748765A1 (en) 2007-02-07
TW200600118A (en) 2006-01-01
TR200501948A2 (tr) 2006-01-23
EP1748765A4 (en) 2009-11-18
US20050266031A1 (en) 2005-12-01
US20090176884A1 (en) 2009-07-09
US20140142187A1 (en) 2014-05-22
WO2005115353A1 (en) 2005-12-08
CN1988893A (zh) 2007-06-27
EP2465497A1 (en) 2012-06-20
US10238640B2 (en) 2019-03-26
CA2567075A1 (en) 2005-12-08
US20170065567A1 (en) 2017-03-09
CA2567075C (en) 2013-05-14
MXPA06013481A (es) 2007-01-23

Similar Documents

Publication Publication Date Title
ZA200504239B (en) Pharmaceutical suspension composition
IL177480A0 (en) Pharmaceutical composition
IL223545A0 (en) Pharmaceutical compositions
IL179809A0 (en) Pharmaceutical compositions
GB0408308D0 (en) Pharmaceutical compositions
IL186336A0 (en) Pharmaceutical composition
PL1837019T3 (pl) Kompozycja farmaceutyczna rozpadająca się w ustach
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
EP1937255A4 (en) PHARMACEUTICAL COMPOSITION
EP1862184A4 (en) PHARMACEUTICAL COMPOSITION
HU0401177D0 (en) Pharmaceutical composition
GB2411355B (en) Pharmaceutical composition
ZA200701932B (en) Pharmaceutical composition
GB0425255D0 (en) Pharmaceutical composition
ZA200701931B (en) Pharmaceutical composition
HUP0401176A2 (en) Pharmaceutical composition having prpkinetic effect
EP1747205A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0502792D0 (en) Pharmaceutical compositions
GB0400971D0 (en) Pharmaceutical compositions
GB0407351D0 (en) Pharmaceutical compositions
GB0411502D0 (en) Pharmaceutical compositions
GB0402799D0 (en) Pharmaceutical composition
GB0425256D0 (en) Pharmaceutical composition
GB0425259D0 (en) Pharmaceutical composition
GB0511801D0 (en) Pharmaceutical composition